SUMMARY Sixteen girls with Turner's syndrome aged 7*9-15-2 years (bone ages 7-0-11-8 years) were given methionyl growth hormone (somatrem) 4 IU/M2 body surface daily, corresponding to 0-9 IU/kg/week. During one year of treatment their mean (SD) height velocity increased from 3-4 (0.9) to 7-2 (1-7) cm/year and height prediction from 148-2 (4-4) to 150-0 (4.4) cm. All the girls except one had a height velocity increment of more than 2 cm/year and these velocities are above the age references for girls with Turner's syndrome. The girl with a low growth response had antibodies against growth hormone with high binding capacity (3.7 U/l). The height velocity increment was inversely correlated with age and bone age, but this might be partly due to the somewhat higher dosage/M2 body surface and kg body weight that the younger patients were given because of the rounding off of the dose. The better results of our study compared with those of other workers who used similar dosages but did not give the drug as often suggest that giving it daily might have increased the growth response as it does in children deficient in growth hormone.
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Turner's syndrome comprises a number of physical abnormalities including sexual infantilism, webbed neck, cubitus valgus, and poor growth velocity that results in short stature. The growth pattern has been well documented, and the reported mean adult height varies between 141-0 and 147-8 cm.1-3
The mechanism underlying this failure to grow is not known, but it is generally believed that the defect is primarily cellular.4 Peak plasma concentrations of growth hormone have been reported as normal by some authors but as low by others after various pharmacological provocation tests. 5 Results Table 2 shows the individual growth velocities before and during treatment with somatrem, and the increments while receiving treatment. There was a significant increase in the mean growth velocity from 3-4 to 7-2 cm/year in the first 12 months (p<0O001). When compared with the Turner growth velocity reference curves24 all growth velocities before treatment were within the reference range, whereas all growth velocities after the start of treatment except one were well above this range (fig 1) . The mean cumulative growth velocities are shown in fig 2. During the first year of treatment the mean (SD) increase in bone age was 1*0 (0.4) years when assessed by the method of Tanner and Whitehouse23 and 1.1 (0-8) when assessed by that of Greulich and Pyle. 27 The increase in bone age assessed by the method of Tanner and Whitehouse was 0-4 (0-3) in the first semester, not statistically different from that in the second semester (0.6 (0-3)). According to the method of Greulich and Pyle the increase in bone age during the first semester was 0-2 (0.4), significantly less than that in the second semester (0.9 (0-6), p<0O001). The mean (SD) height prediction (based on the bone age readings with the Greulich and Pyle atlas and the Bailey Pinneau There were no significant changes of the triceps, biceps, and subscapular skinfold thicknesses, weight for height, muscle/bone area, or the ratio of the sitting height:subischial leg length expressed as standard deviation score for bone age.
There was a weak but significant negative correlation between the growth velocity increment after 12 months of treatment and chronological age (r=-0-51, p<0.05), and bone age (r=-0-55, p<005). The rounding off of the growth hormone dose meant that the average older girls received less growth hormone per m2 body surface or kilogram body weight than the younger girls. This is illustrated by the negative correlation between age and growth hormone dose in IU/kg/week (r=-0-67, p<0-01). As the height velocity increment is also correlated with the growth hormone dose in IU/kg/ week (r=0-54), it is possible that the inverse correlation between height velocity increment and age is at least partly a dosage effect. Neither the growth velocity before treatment nor the delay in bone maturation correlated with the growth velocity increment after 12 months of treatment. The growth velocity increment after four weeks did not correlate significantly with the increment after 12 months (r=0-43), but did after 8 and 12 weeks (r=057, p<005, and r=0-73, p<001, respectively).
The maximum growth hormone concentrations after arginine infusion were between 2 and 68 mU/l (mean 24), after exercise between 1 and 50 mU/l (mean 22), and after growth hormone releasing factor between 7 and 137 mU/l (mean 40). In six girls (aged 9-3 to 13-8 years, mean 11.9) the peak growth hormone concentrations during the two provocation tests were below 20 mU/l. When the patient with the high concentration of antibodies against growth hormone was excluded, the mean (SD) increment was 3-0 (0.7) cm-year compared with 4*5 (1.5) cm/year in the remaining children. In eight children antibodies against E coli proteins were detectable before treatment, but the titres were low (0.1-0.8). During treatment the number of children in whom the antibodies were detected did not increase and the titres remained the same.
No adverse reactions were noted, compliance was good, and the girls were enthusiastic about the results. There were no problems with the daily injections of growth hormone.
Discussion
The effect of pituitary derived growth hormone on patients with Turner's syndrome has been described in a number of studies. Soyka Ross et al3l studied the dose response association between short term linear growth and growth hormone dosage, given three times a week. Lower leg length showed no increase with a growth hormone dose of 0-15 IU/kg/week, but increased significantly with doses of 0-45 and 1-35 IU/kg/week. The higher dose of 1-35 IU/kg was no more effective than that of 0*45 IU/kg. In our study, daily somatrem (0-9 IU/kg/week) resulted in a considerable increment in growth velocity, which is higher Bone age advanced by 1-0 (0-4) years and the average height prediction increased by 1-8 cm. These preliminary results and the results of the American collaborative study '6 30 suggest that the increased growth velocity may result in higher final heights. Long term follow up is required however, to determine whether this will be the case.
